- Home
- LPTH vs SGMT Comparison
LPTH vs SGMT Comparison
Compare LPTH & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTH
- SGMT
- Stock Information
- Founded
- LPTH 1985
- SGMT 2006
- Country
- LPTH United States
- SGMT United States
- Employees
- LPTH N/A
- SGMT N/A
- Industry
- LPTH Semiconductors
- SGMT
- Sector
- LPTH Technology
- SGMT
- Exchange
- LPTH Nasdaq
- SGMT Nasdaq
- Market Cap
- LPTH 128.3M
- SGMT 131.4M
- IPO Year
- LPTH 1996
- SGMT 2023
- Fundamental
- Price
- LPTH $2.93
- SGMT $7.72
- Analyst Decision
- LPTH Strong Buy
- SGMT Strong Buy
- Analyst Count
- LPTH 3
- SGMT 6
- Target Price
- LPTH $4.67
- SGMT $23.17
- AVG Volume (30 Days)
- LPTH 183.9K
- SGMT 3.1M
- Earning Date
- LPTH 05-15-2025
- SGMT 08-13-2025
- Dividend Yield
- LPTH N/A
- SGMT N/A
- EPS Growth
- LPTH N/A
- SGMT N/A
- EPS
- LPTH N/A
- SGMT N/A
- Revenue
- LPTH $33,626,969.00
- SGMT N/A
- Revenue This Year
- LPTH $19.58
- SGMT N/A
- Revenue Next Year
- LPTH $44.50
- SGMT N/A
- P/E Ratio
- LPTH N/A
- SGMT N/A
- Revenue Growth
- LPTH 2.59
- SGMT N/A
- 52 Week Low
- LPTH $1.04
- SGMT $1.73
- 52 Week High
- LPTH $4.42
- SGMT $9.60
- Technical
- Relative Strength Index (RSI)
- LPTH 55.46
- SGMT 71.77
- Support Level
- LPTH $2.90
- SGMT $6.56
- Resistance Level
- LPTH $3.25
- SGMT $9.60
- Average True Range (ATR)
- LPTH 0.18
- SGMT 1.09
- MACD
- LPTH -0.02
- SGMT 0.24
- Stochastic Oscillator
- LPTH 25.72
- SGMT 73.17
About LPTH LightPath Technologies Inc.
LightPath Technologies Inc is a manufacturer, distributor, and integrator of proprietary optical components and assemblies. It is also engaged in the research and development for optical solutions for the traditional optics markets and communications markets. The company's business based on the following product groups: precision molded optics, specialty products, and infrared products. It currently serves the following major markets, distribution and catalog, laser, industrial, instrumentation, telecommunications, and defense.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.